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1-(cyclohexylmethyl)-1H-indazole-3-carboxamide 
(AB-CHMINACA)
In accordance with Article 5 of Council Decision 2005/387/JHA on 
the information exchange, risk assessment and control of new 
psychoactive substances
About this series
EMCDDA–Europol Joint Report publications examine the detailed information 
provided by the EU Member States on individual new psychoactive substances. 
Information is collected from the Reitox network, the Europol National Units and the 
national competent authorities of the European Medicines Agency.
Each Joint Report serves as the basis upon which the decision to conduct a risk 
assessment of the new psychoactive substance is taken. It is part of the three-step 
procedure involving information exchange, risk assessment and decision-making in the 
framework of Council Decision 2005/387/JHA.
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I 1. Introduction
Article 5.1 of Council Decision 2005/387/JHA (1) (hereinafter 
the ‘Council Decision’) stipulates that ‘Where Europol and the 
EMCDDA, or the Council, acting by a majority of its members, 
consider that the information provided by the Member State 
on a new psychoactive substance merits the collection of 
further information, this information shall be collated and 
presented by Europol and the EMCDDA in the form of a Joint 
Report.’ The Joint Report shall be submitted to the Council of 
the European Union, the European Medicines Agency (EMA), 
and the European Commission.
In March 2017, the EMCDDA and Europol examined the 
available information on the new psychoactive substance 
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-
1H-indazole-3-carboxamide, commonly known as AB-
CHMINACA, through a joint assessment based upon the 
following criteria:
1. the amount of the material seized;
2. evidence of organised crime involvement;
3. evidence of international trafficking;
4. analogy with better-studied compounds;
5. evidence of the potential for further (rapid) spread; and,
6. evidence of cases of serious intoxication or fatalities.
The EMCDDA and Europol agreed that the information 
collected on AB-CHMINACA satisfied criteria 1, 4 and 6. The 
two agencies therefore concluded that sufficient information 
had been accumulated to merit the production of a Joint 
Report on AB-CHMINACA as stipulated by Article 5.1 of the 
Council Decision.
I 2. Information collection process
In compliance with the provisions of the Council Decision, on 
25 April 2017 the EMCDDA and Europol launched a procedure 
for the collection of information on AB-CHMINACA, in order to 
prepare the Joint Report. The information was collected 
mainly through the Reitox national focal points in the Member 
States, Turkey and Norway as well as the Europol National 
Units. In addition, the EMA collected information through the 
national competent authorities responsible for human and 
veterinary medicinal products in the Member States as well as 
in Norway, Iceland and Liechtenstein. The EMA also provided 
information as relevant to the centralised procedure for 
authorising medicinal products. The information collection 
process was largely concluded by 6 June 2017.
(1) OJ L 127, 20.5.2005, p. 32.
Information collected by Europol
Europol asked the Europol National Units to provide 
information on:
 ¡ the level of production of AB-CHMINACA in their country;
 ¡ the level of distribution of AB-CHMINACA in their country;
 ¡ the level of trafficking of AB-CHMINACA in their country, 
both for internal, transit or export purposes;
 ¡ the number of seizures of AB-CHMINACA in their country, 
the total amount of the seizures, country of origin, details 
on the physical forms (including photos);
 ¡ the role of organised crime or criminal groups, in the 
production, distribution and trafficking of AB-CHMINACA in 
their country;
 ¡ any known aspect of violence and/or money laundering 
relating to the production and trafficking of AB-CHMINACA.
Europol received responses from 15 Member States (2).
Information collected by the EMA
According to Article 5.3 of the Council Decision, the EMA 
requested that the national competent authorities responsible 
for human and veterinary medicinal products in the Member 
States, Norway, Iceland and Liechtenstein, provide information 
on whether:
 ¡ the new psychoactive substance AB-CHMINACA has 
obtained a marketing authorisation;
 ¡ the new psychoactive substance AB-CHMINACA is the 
subject of an application for a marketing authorisation;
 ¡ a marketing authorisation that had been granted in respect 
of the new psychoactive substance AB-CHMINACA has 
been suspended.
Twenty-three countries provided a response to the EMA’s 
request regarding human and/or veterinary medicinal 
products (3). The EMA also provided information as relevant to 
the centralised procedure for authorising human and 
veterinary medicinal products.
Furthermore, in anticipation of Article 7.3 of the Council 
Decision in relation to the manufacturing of medicinal 
products in the European Union, the EMA also requested 
(2) In alphabetical order: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech 
Republic, Finland, Germany, Greece, Latvia, Lithuania, Luxembourg, Romania, 
Slovakia and Slovenia.
(3) Austria, Belgium, Denmark, Estonia, Finland, Germany, Greece, Ireland, Latvia, 
Norway, Poland, Spain, Sweden and the United Kingdom provided a response in 
relation to human and veterinary medicinal products. Croatia, Czech Republic, 
Hungary, Italy and the Netherlands provided a response in relation to human 
medicinal products. France, Portugal, Slovakia and Slovenia provided a response 
in relation to veterinary medicinal products.
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information on whether the new psychoactive substance 
AB-CHMINACA is used to manufacture a medicinal product:
 ¡ which has been granted a marketing authorisation;
 ¡ for which an application has been made for a marketing 
authorisation;
 ¡ for which a marketing authorisation has been suspended 
by a competent authority.
Twenty-three countries (4) provided a response to the EMA’s 
request in this regard. The EMA also provided information as 
relevant to the centralised procedure for authorising human 
and veterinary medicinal products.
Information collected by the EMCDDA
The EMCDDA collected information through:
 ¡ a structured questionnaire to the Reitox national focal 
points. The EMCDDA received replies from 27 Member 
States (5), as well as Turkey and Norway;
 ¡ reports previously provided to the European Union Early 
Warning System, including EMCDDA–Europol Reporting 
Forms and Progress Reports and Final Reports;
 ¡ routine monitoring of open source information;
 ¡ a specific information request to the World Health 
Organization on whether or not AB-CHMINACA is under 
assessment by the United Nations system;
 ¡ a search of open source information conducted specifically 
for the production of the Joint Report which included: 
scientific and medical literature, official reports, grey 
literature, internet drug discussion forums and related 
websites (hereafter, ‘user websites’), and, online vendors 
selling AB-CHMINACA.
Thus, the information included in sections 3.2.1 and 3.3 of the 
Joint Report was provided by Europol, while the EMCDDA 
provided information included in sections 3.1, 3.2.2, 3.4, 3.5, 
3.6, 3.7, 3.8.1, 3.8.2 and 3.8.3 (in part). The information 
included in sections 3.8.3 (in part) and 4 was provided by the 
EMA. Images of the seizures and collected samples reported 
to the EMCDDA and Europol are provided in Annex 1 and 
Annex 2, respectively.
(4) Austria, Belgium, Denmark, Estonia, Finland, Germany, Greece, Ireland, Latvia, 
Norway, Poland, Spain, Sweden and the United Kingdom provided a response in 
relation to human and veterinary medicinal products. Croatia, Czech Republic, 
Hungary, Italy and the Netherlands provided a response in relation to human 
medicinal products. France, Portugal, Slovakia and Slovenia provided a response 
in relation to veterinary medicinal products.
(5) A reply was not received from Slovakia. 
 3.  Information required by Article 5.2 of 
the Council Decision
The order and titles of subsections 3.1 to 3.8 and section 4, 
below, are as they appear in Article 5.2(a) to (h) and Article 
5.3(a) to (c) of the Council Decision; sections are cross-
referenced with those set down in the Council Decision.
 3.1  Chemical and physical description, including 
the names under which the new psychoactive 
substance is known (Article 5.2(a) of the 
Council Decision)
Chemical description and names
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-
1H-indazole-3-carboxamide is commonly referred to as 
AB-CHMINACA (6).
AB-CHMINACA is a synthetic cannabinoid receptor agonist. It 
has an indazole core, which is a common structural feature in 
many of the synthetic cannabinoids monitored by the 
EMCDDA.
Two synthetic cannabinoid receptor agonists have been 
recently controlled under Schedule II of the United Nations 
Convention on Psychotropic Substances of 1971: JWH-018 (7) 
and AM-2201 (8). In addition, MDMB-CHMICA, 5F-APINACA 
(5F-AKB48) and XLR-11 will be included in the same schedule.
The molecular structure, molecular formula and molecular 
mass of AB-CHMINACA are provided in in Figure 1.
(6) The common name for the substance is derived after its structural features. 
Different naming systems exist and are used for applying short/code names to 
synthetic cannabinoids.
(7) Naphthalen-1-yl(1-pentyl-1H-indol-3-yl)methanone
(8) 1-(5-Fluoropentyl)-1H-indol-3-yl]-(naphthalen-1-yl)methanone
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AB-CHMINACA has a positional isomer, where the 
cyclohexylmethyl tail is attached to the nitrogen at position 2 
of the indazole, which has been identified in products in Japan 
(Longworth et al., 2016) (9). It is unknown whether this 
regiosiomer represents a manufacturing impurity or was 
intentionally synthesised. Both isomers have the same 
molecular formula and molecular weight which result in very 
similar mass spectra. However, they can be differentiated 
based on their retention time and it would be expected that 
the infrared (IR) and nuclear magnetic resonance spectra 
(NMR) would be different. AB-CHMINACA contains 
a stereocentre thus allowing for the existence of a pair of 
enantiomers (10), (R)- and (S)-AB-CHMINACA. The synthesis 
of (S)-AB-CHMINACA was first described in the patent 
literature in 2009 (Buchler et al., 2009). Based on the 
literature and the most likely precursors to be used, an 
(S)-configuration of the stereocentre could be expected.
There is no representative information on the enantiomeric 
composition of the samples of AB-CHMINACA detected within 
the European Union, which in part may reflect the fact that 
stereochemical analysis is not routinely undertaken in forensic 
laboratories. Differentiation of enantiomers is possible using 
the following techniques: chiral chromatography, vibrational 
circular dichroism (VCD) spectroscopy and/or electronic 
circular dichroism (ECD) spectroscopy.
Commonly used names:  
AB-CHMINACA
(9) The positional isomer of AB-CHMINACA is referred to as ‘AB-CHMINACA 
2-isomer’ by Longworth et al.
(10) Optical isomers (or enantiomers) have the same physico-chemical 
characteristics, differing only in their interaction with plane polarized light.
FIGURE 1 
Molecular structure, molecular formula and molecular mass 
of AB-CHMINACA
N
N
O
NH
O
NH2
AB-CHMINACA
Molecular formula C20H28N4O2
Molecular mass 356.47
Systematic (IUPAC) name:  
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-
1H-indazole-3-carboxamide
Chemical Abstracts names:  
N- [1- (aminocarbonyl) - 2- methylpropyl] - 1- (cyclohexylmethyl) - 1H- 
indazole- 3- carboxamide;  
N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-
1H-indazole-3-carboxamide (S enantiomer)
Other chemical names:  
N-(1-carbamoyl-2-methyl-propyl)-1-(cyclohexylmethyl)
indazole-3-carboxamide; 
N-[(1S)-1-carbamoyl-2-methyl-propyl]-1-(cyclohexylmethyl)
indazole-3-carboxamide (S enantiomer);  
N-[1-(aminokarbonyl)-2-metylpropyl]-1-(cyclohexylmetyl)-1H-
indazol-3-karboxamid (Swedish)
Chemical Abstracts Service (CAS) registry numbers (11): 
1805788-79-7 AB-CHMINACA racemate 
1185887-21-1 (S)-AB-CHMINACA
IUPAC International Chemical Identifier Key (InCHI Key) (12):  
KJNZIEGLNLCWTQ-UHFFFAOYSA-N AB-CHMINACA
 racemate 
KJNZIEGLNLCWTQ-KRWDZBQOSA-N (S)-AB-CHMINACA
The REACH registered substances database hosted by the 
European Chemicals Agency (ECHA) was searched using 
the CAS registry numbers listed above. The searches returned 
no hits.
Physical description
In its pure form AB-CHMINACA is a white crystalline solid 
(Longworth et al., 2016). AB-CHMINACA is soluble in organic 
solvents such as ethanol, dimethyl sulfoxide (DMSO) and 
dimethyl formamide (DMF). The solubility of AB-CHMINACA in 
these solvents is approximately 3, 10 and 5 mg/ml 
respectively. AB-CHMINACA is also soluble in deuterated 
chloroform (CDCl3) (Slovenian National Forensic Laboratory, 
2015). AB-CHMINACA is sparingly soluble in aqueous buffers 
(Cayman Chemical Company).
The measured melting point for AB-CHMINACA is 88.5-92.5°C 
(Longworth et al., 2016).
AB-CHMINACA has been typically seized as herbal material 
and in powder form. It has also been detected in liquids and 
(11) The Chemical Abstract Service Registry Number (CAS RN) is a unique 
numeric identifier assigned by the Chemical Abstract Service Division of the 
American Chemical Society to a specific, single chemical substance.
(12) InChI Key is a unique, non-proprietary stuctural identifier of chemical 
substances useful in electronic sources.
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blotters. A more detailed description of seizures and collected 
samples can be found in section 3.2.1 and section 3.2.2.
Chemical stability and typical reactions
For long term storage it is recommended that AB-CHMINACA, 
supplied as a crystalline solid, is stored at -20ºC (Cayman 
Chemical Company).
Storage in solution or under non-ideal conditions (e.g. high 
humidity or elevated temperatures) can lead to hydrolysis of 
the carboxylic ester function. Ester hydrolysis can be 
expected to occur during smoking as it was observed by 
analysis of smoke condensates of AB-CHMINACA (Auwärter 
2017). Most of the known free carboxylic acids formed by 
hydrolysis of similar compounds are not active or are poorly 
active at the CB
1
-receptor (Buchler, 2009 and 2011).
Detection and analysis
Reference materials are claimed to be available for (S)-AB-
CHMINACA (13).
Literature on the analytical identification of AB-CHMINACA 
includes:
 ¡ gas chromatography–mass spectrometry (GC-MS), Fourier 
transform infrared spectroscopy attenuated total 
reflectance (FTIR-ATR), high performance liquid 
chromatography time-of-flight (HPLC-TOF) and nuclear 
magnetic resonance spectroscopy (NMR) (Slovenian 
National Forensic Laboratory, 2015);
 ¡ GC-MS (Akamatsu and Yoshida, 2016, Dronova et al., 2016, 
Langer et al., 2016, Uchiyama et al., 2015);
 ¡ liquid chromatography – mass spectrometry (LC-MS) 
(Dronova et al., 2016, Uchiyama et al., 2015);
 ¡ FTIR (Langer et al., 2016 and Longworth et al., 2016);
 ¡ NMR (Buchler et al., 2009, Langer et al., 2016 and 
Longworth et al., 2016), ultraviolet-visible spectroscopy 
(UV-VIS) (Langer et al., 2016);
 ¡ low resolution – mass spectrometry (LRMS) and high 
resolution mass spectrometry (HRMS) (Longworth et al., 
2016);
 ¡ direct analysis in real time (DART-MS) and liquid 
chromatography/electrospray ionization quadrupole 
time-of-flight mass spectrometry (LC/QTOFMS) (Nie et al., 
2016).
(13) http://shop.chiron.no/main.aspx?page=article&artno=C10464.20-100-ME&
gid=&gidlevel=&pid=; https://www.caymanchem.com/product/15434;  
https://www.trc-canada.com/product-detail/?CatNum=A105960&-
CAS=1185887-21-1&Chemical_Name=AB-CHMINACA&Mol_Formula=C%E2%8
2%82%E2%82%80H%E2%82%82%E2%82%88N%E2%82%84O%E2%82%82
Quantification of AB-CHMINACA in products can be carried 
out according to the general procedure described by the 
(UNODC, 2013).
 3.2  Information on the frequency, circumstances 
and/or quantities in which a new psychoactive 
substance is encountered, and information on the 
means and methods of manufacture of the new 
psychoactive substance (Article 5.2(b) of the 
Council Decision)
The data reported to Europol discussed in section 3.2.1 may 
overlap with the data reported to the EMCDDA discussed in 
section 3.2.2.
3.2.1 Information provided to Europol
Europol received replies from 15 Member States (Austria, 
Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Finland, 
Germany, Greece, Latvia, Lithuania, Luxembourg, Romania, 
Slovakia and Slovenia).
Six countries reported that they have no available information 
on AB-CHMINACA (Belgium, Cyprus, Czech Republic, Greece, 
Luxembourg and Slovenia).
The remaining nine countries provided limited information on 
AB-CHMINACA (Austria, Bulgaria, Croatia, Finland, Germany, 
Latvia, Lithuania, Romania and Slovakia).
The level of production
No information was received in relation to the production of 
AB-CHMINACA.
The level of distribution
At least 271 seizures were reported by 10 Member States: 
Austria (2), Bulgaria (3), Croatia (30), Czech Republic (2), 
Finland (minor seizures in 2014, 2015 and 2016, exact number 
unspecified), Germany (152), Latvia (62), Lithuania (6), 
Romania (2) and Slovakia (9).
 ¡ Austria: 2 small seizures of herbal material, containing other 
synthetic cannabinoids. The packages were labelled ‘Red 
Dub Herbal Blend’.
 ¡ Bulgaria: 3 seizures amounting to 37 g, which were 
delivered from Spain to Bulgaria and from the Netherlands 
to Bulgaria. At least one of the packages was labelled ‘MMB 
CHMINACA – 2g Legal Research Chemical Reagent Use 
Only’.
 ¡ Croatia: seizures of herbal material were reported in 2015 
(30 seizures, amounting to almost 1 kg), 2016 (7, 19.26 g) 
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and 2017 (1, 0.66 g). In most cases the seizures contained 
other synthetic cannabinoids.
 ¡ Finland: unspecified number of seizures made in 2014, 
2015 and 2016.
 ¡ Germany: 144 small seizures of herbal smoking mixtures 
made in 2016, one of the seizures amounted to 284 g; and 
8 seizures in 2017, most of which were in the form of herbal 
material, which amounted to 57 g.
 ¡ Latvia: reported 62 seizures, among which there was one 
seizure amounting to 495 g.
 ¡ Lithuania: 6 seizures made in 2017, which amounted to 
8.578 g. Lithuania reported that ‘AB-CHMINACA is one of 
the most frequently seized synthetic cannabinoids, but in 
general the distribution level of NPS is not very high within 
the country’.
 ¡ Romania: 2 seizures amounting to 9.4 kg and 5.7 kg.
 ¡ Slovakia: a total of 9 small seizures in various physical 
forms were reported. Seizures were made in 2014 (3), 
2015 (5) and 2016 (1). See Annex 2 for more details.
The level of trafficking
Information related to trafficking routes is limited to the 
seizures reported above.
3.2.2 Information provided to the EMCDDA
The EMCDDA received responses from 27 Member States (5), as 
well as from Turkey and Norway. Of these, 24 Member States (14), 
Turkey and Norway reported detections of AB-CHMINACA (15).
It is important to note that detections of AB-CHMINACA may 
be under-reported since the substance is not routinely 
screened for. Three Member States (Austria, Slovenia and 
Sweden) and Norway reported that AB-CHMINACA is part of 
routine screening in some (but not all) of their laboratories.
Seizures
In total, 6 422 seizures of AB-CHMINACA were reported to the 
EMCDDA by 24 Member States, Norway and Turkey, as 
follows: Austria (10 seizures), Belgium (24), Bulgaria (17), 
Croatia (45), Denmark (2), Estonia (18), Finland (114), France 
(26), Germany (2), Greece (3), Hungary (1 723), Italy (1), Latvia 
(221), Lithuania (62), Luxembourg (4), the Netherlands (7), 
Norway (9), Poland (1 793), Portugal (3), Romania (3), Slovakia 
(6), Slovenia (2), Spain (7), Sweden (121), Turkey (1 801) and 
(14) Four Member States (Czech Republic, Cyprus, Ireland and Malta) reported no 
detections of AB-CHMINACA.
(15) ‘Detections’ is an all-encompassing term and may include seizures and/or 
collected and/or biological samples that are analytically confirmed. Seizure 
means a substance available (seized) through law enforcement activities (police, 
customs, border guards, etc.). Collected samples are those that are actively 
collected by drug monitoring systems (such as test purchases) for monitoring 
and research purposes. Biological samples are those from human body fluids 
(urine, blood, etc.) and/or specimens (tissues, hair, etc.). 
the United Kingdom (398). The majority of the seizures 
comprise police and customs cases, with additional seizures 
taking place in custodial settings.
Seizures included herbal materials, powders, liquids, blotters 
and unspecified physical forms. A summary is provided below.
Herbal material
 ¡ 4 066 seizures of AB-CHMINACA in herbal material were 
reported by 24 countries: Austria, Bulgaria, Croatia, 
Denmark, Estonia, Finland, France, Germany, Greece, 
Hungary, Italy, Latvia, Lithuania, Luxembourg, the 
Netherlands, Norway, Poland, Portugal, Romania, Slovakia, 
Slovenia, Spain, Sweden and the United Kingdom, 
amounting to over 40 kg, plus more than 145 000 packages 
of commercially labelled herbal smoking mixtures (16) 
weighing 1-3 g each. In addition, Turkey reported 1 757 
seizures of herbal material amounting to almost 150 kg (17).
 ¡ The largest single seizure of AB-CHMINACA in herbal 
material was reported by Spain. In the frame of ‘Operation 
Alimaya’, a large-scale operation carried out in Alicante in 
March 2016, a total of 145 157 packages (of 1-3 g each, 
containing also AMB-FUB and AB-FUBINACA) and 2 bags 
(of 2 kg each, containing also AMB-FUB) were seized.
 ¡ Other large single seizures of herbal materials were reported 
by Lithuania (3.9 kg in the form of briquettes with Euro signs, 
seized by Police) and Bulgaria (2 kg, no further information).
 ¡ Hungary reported around 1 700 seizures of herbal material 
amounting to 16 kg.
 ¡ In herbal material, AB-CHMINACA was commonly found 
mixed with other synthetic cannabinoids. In 15 seizures, 
samples contained stimulants: Hungary (8 cases; 
amphetamine, pentedrone, clephedrone) and Poland 
(7 cases; amphetamine, alpha-POP and clephedrone).
Powder
 ¡ 281 seizures of powder were reported by 22 countries: 
Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, 
France, Germany, Hungary, Latvia, Lithuania, Luxembourg, 
the Netherlands, Norway, Poland, Romania, Slovakia, 
Slovenia, Spain, Sweden, Turkey and the United Kingdom, 
amounting to a total of more than 43.8 kg.
 ¡ The largest single seizures of AB-CHMINACA in powder form 
were reported by: Luxembourg (4.8 kg seized by customs in 
a FedEx delivery), France (3.5 kg of white powder seized at 
Roissy Airport, coming from China and headed to Austria) 
and Spain (2 kg of powder seized at Madrid-Barajas Airport, 
coming from China and headed to France).
(16) Products seized include: ‘Aromatic Pot Pourri’, ‘Jamaican Gold Supreme’, 
‘Jamaican Gold Extreme’, ‘Yama’, ‘Bonzai Summer Boost’, ‘Bonzai Winter Boost’, 
‘Bonzai Citrus’, ‘Blaze’, ‘Bubblegum’, ‘Manga Xtreme’, ‘Manga XXL’, ‘V.I.P.’, ‘Love’, 
‘R&B’, and ‘King Size Slim Rolling Papers’.
(17) Minimum estimate provided by the Turkish national focal point for 2016.
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Liquid
 ¡ Sweden (4 cases) and Finland (3) reported seizures of 
AB-CHMINACA in liquid form, amounting to a total of 293 
ml. The largest seizure was reported by Finland and 
consisted of 50 bottles (225 ml) of “e-liquid” for vaping 
(concentration 3.5 mg/ml).
Other physical forms
 ¡ 178 seizures of AB-CHMINACA in blotter form were 
reported by Poland, amounting to 193.9 g.
 ¡ Additionally, 2 seizures were reported by Lithuania 
amounting to more than 20 kg where no information on the 
physical form was available.
Lithuania provided quantitative information on the purity of 
AB-CHMINACA in eight analysed samples of herbal material 
and one sample where the physical form was not specified. 
The purity of AB-CHMINACA in the samples was in the range 
of 0.15–4.3 % (mean: 1.97 %, median: 2.0 %).
Collected samples
Two collected samples of AB-CHMINACA were reported to the 
EMCDDA from Belgium (1 case) and Poland (1). The case from 
Belgium involved a patient requiring medical treatment at 
a hospital in Antwerp, following ingestion of AB-CHMINACA. 
A sample of white powder collected from the patient was 
found to contain AB-CHMINACA. The sample from Poland 
consisted of a bag of herbal material which also contained 
alpha-PVP.
Biological samples
Serious adverse events with confirmed exposure to 
AB-CHMINACA from biological samples are discussed 
in section 3.4.2.
In addition to these, 551 detections where AB-CHMINACA was 
analytically confirmed in biological samples were reported by 
three Member States: Hungary (537 cases), Sweden (10) and 
Poland (4) (18). Detections include:
 ¡ 52 cases related to persons suspected of driving under the 
influence of drugs (including 10 traffic accidents), all 
reported by Hungary;
 ¡ 484 cases were reported in relation to drug abuse 
(consumption), intoxication or non-fatal intoxication, with 
no further details provided;
 ¡ 15 cases, where the type of event was not specified.
(18) In addition, Turkey reported 902 samples (blood, hair and urine) which may 
contain duplicates and therefore have not been included in the total count.
 3.3  Information on the involvement of organised 
crime in the manufacture or trafficking of the new 
psychoactive substance (Article 5.2(c) of the 
Council Decision)
No information concerning the involvement of organised crime 
in the manufacture and/or trafficking of the AB-CHMINACA 
was provided.
Money laundering aspects
No information was received on money laundering in 
connection with the production and/or trafficking of AB-
CHMINACA.
Violence in connection with production, wholesale and 
distribution
No information was received on incidents of violence in 
connection with the production, wholesale and/or trafficking 
of AB-CHMINACA.
 3.4  A first indication of the risks associated with the 
new psychoactive substance, including the health 
and social risks, and of the characteristics of 
users — Article 5.2(d) of the Council Decision
3.4.1 Health risks
Pharmacology and toxicology
Limited data suggests that AB-CHMINACA is a CB
1
 receptor 
agonist (Longworth, et al., 2016; Moosmann et al., 2017; Wiley 
et al., 2015 (19)) that shares some similarities with the major 
psychoactive constituent of cannabis (–)-trans-Δ9-
tetrahydrocannabinol (THC) and synthetic cannabinoids such 
as JWH-018 and MDMB-CHMICA (EMCDDA, 2017; Järbe and 
Raghav, 2017; Pertwee, 2014; Reggio, 2009).
The acute effects of THC (and consequently cannabis) include: 
relaxation, euphoria, lethargy, depersonalisation, distorted 
perception of time, impaired motor performance, 
hallucinations, paranoia, confusion, fear, anxiety, dry mouth, 
reddening of the conjunctivae of the eyes, tachycardia, and, 
nausea and vomiting. THC also has an abuse liability and 
dependence potential (Pertwee, 2014; Wiley et al., 2016). 
Similar effects to cannabis have been reported for synthetic 
cannabinoids such as AB-CHMINACA. In some cases, the 
effects are reported to be more pronounced/severe 
(EMCDDA, 2017).
(19) Where reported the (S) enantiomer was studied.
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Compared to cannabis, severe and fatal poisoning appears to 
be more common with synthetic cannabinoids (EMCDDA, 
2017; Tait et al., 2016). Poisoning may include rapid loss of 
consciousness/coma, cardiovascular effects (such as 
hypertension, tachycardia, bradycardia, chest pain, myocardial 
infarction and stroke), seizures and convulsions, vomiting/
hyperemesis, delirium, agitation, psychosis, and, aggressive 
and violent behaviour. Sudden death has also been reported. 
The mechanisms of this toxicity are poorly understood (Tai 
and Fantegrossi, 2016), but factors that are likely to play an 
important role are the potency of the substances and the 
doses that users are exposed to. In addition, some of the 
effects of poisoning — such as loss of consciousness or 
behavioural effects — may place users at additional risks such 
as choking on vomitus, drowning, or self-harm.
There is no antidote to poisoning caused by synthetic 
cannabinoids.
In general, the use of herbal smoking mixtures containing 
synthetic cannabinoids appears to pose a high risk of 
poisoning. This is because manufacturers guess the amount 
of cannabinoid (s) to add to the herbal material and the 
manufacturing process makes it difficult to dilute them 
sufficiently and distribute them consistently throughout the 
material. This can result in mixtures that contain a large 
amount of highly potent cannabinoid, as well as ‘hot pockets’ 
where the cannabinoid is highly concentrated within parts of 
the herbal material (e.g. Schäper, 2016). Together, this makes 
it difficult for users to control the dose that they are exposed 
to. As these mixtures are typically smoked as cigarettes 
(‘joints’), users can inadvertently administer a toxic dose; in 
some cases, a small number of puffs from a cigarette have 
been sufficient to cause severe poisoning. Reflecting these 
risks, smoking mixtures have caused a large number of 
outbreaks of mass poisonings in recent years (Adams et al., 
2017; Kasper et al., 2015; Schwartz et al., 2015; Shevyrin et al., 
2015; Trecki et al., 2015; Tyndall et al., 2015).
While there is limited data for AB-CHMINACA, the chronic 
health risks might share similarities to cannabis and other 
synthetic cannabinoids. This may include dependence.
3.4.2 Serious adverse events
Acute intoxications
A total of seven acute intoxications with confirmed exposure 
to AB-CHMINACA were reported by Belgium (1 case), France 
(1), Hungary (3) and the United Kingdom (2). The cases 
occurred between 2014 and 2016. No further details are 
available on the cases from Hungary.
In two out of the remaining four cases, no other substances 
were detected. In the other two cases other substances 
detected included synthetic cannabinoids and an opioid. In all 
four cases, the clinical features of the poisoning were typical 
of those reported for synthetic cannabinoids.
Deaths
A total of 31 deaths with confirmed exposure to AB-
CHMINACA were reported by Croatia (1 case), Germany (4), 
Hungary (11), Poland (2), Sweden (5) and the United 
Kingdom (8). The cases occurred between 2014 and 2017.
Of the deaths, 24 were male (77 %), one was female (3 %); the 
data was missing for six cases (20 %). The males were aged 
between 16 and 66 years (n=23; mean 29.7, median 26.5); the 
female was aged 38. In six cases, no other substances were 
detected. In two cases, it was unknown if other substances 
were detected. In the remaining cases, other substances were 
detected including central nervous system depressants (such 
as alcohol, synthetic cannabinoids, opioids and 
benzodiazepines). Where known, many of the cases were found 
dead; in at least some cases the individuals were in a home 
environment or prison. In at least seven cases, AB-CHMINACA 
was the cause of death or contributed to the death.
3.4.3 Characteristics of users
Similar to other synthetic cannabinoids, AB-CHMINACA is sold 
and used as a ‘legal’ substitute for cannabis (EMCDDA, 2009; 
EMCDDA, 2017). The most common way of using it is by 
smoking a cigarette of herbal mixture that has been laced with 
the substance. Because these products rarely state the 
ingredients, most users will be unaware that they are using 
AB-CHMINACA.
People who use AB-CHMINACA may include recreational 
users, high-risk drug users and groups who experiment with 
the substance (such as psychonauts). This may also include 
individuals who are subject to drug testing (such as people in 
drug treatment, prisoners and drivers) because some drug 
tests/screens will be unable to detect AB-CHMINACA. In the 
past few years, synthetic cannabinoids have become 
increasingly used by vulnerable groups (such as the homeless 
and prisoners).
3.4.4 Social risks
While there is limited data for AB-CHMINACA, the social risks 
might share some similarities with cannabis and other 
synthetic cannabinoids.
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Of particular note is that synthetic cannabinoids are 
increasingly used by vulnerable groups, such as the homeless 
and prisoners. Reports suggest that this has caused new 
health and social problems as well as exacerbated existing 
ones for these groups. For example, in prisons, alongside the 
adverse health effects, the market in synthetic cannabinoids 
has been linked to an increase in aggression, violence, bullying 
and debt. In some cases this has caused a serious threat to 
the overall safety and security of the prison environment 
(Blackman and Bradley, 2017; HMIP, 2015; Ralphs et al., 2017; 
User Voice, 2016).
 3.5  Information on whether or not the new substance 
is currently under assessment, or has been under 
assessment, by the UN system (Article 5.2(e) of 
the Council Decision)
The World Health Organization is the specialised United 
Nations agency designated for the evaluation of the medical, 
scientific and public health aspects of psychoactive 
substances under the Single Convention on Narcotic Drugs, 
1961 and the Convention on Psychotropic Substances, 1971.
On 1 May 2017, the World Health Organization informed the 
EMCDDA that AB-CHMINACA is currently not under 
assessment and has not been under assessment by the UN 
system.
On 12 May 2017, the WHO informed the EMCDDA that 
AB-CHMINACA will be reviewed at the 39th meeting of the 
WHO Expert Committee on Drug Dependence (ECDD) that 
will be held on 16–20 November 2017. At the time of writing 
this report neither a critical review nor a written 
recommendation had been published.
 3.6  The date of notification on the Reporting Form 
of the new psychoactive substance to the 
EMCDDA or to Europol (Article 5.2(f) of 
the Council Decision)
The first official EMCDDA–Europol notification of AB-CHMINACA 
dates from 10 April 2014 from the Latvian national focal point. 
The Reporting Form details a seizure of eight plastic bags 
containing herbal material amounting to 3.81 g that were seized 
in February 2014 by the Municipal Police in Riga. The substance 
was analytically identified by the Forensic Service Department of 
the State Police by GC-MS and the Latvian Institute of Organic 
Synthesis confirmed the structure using NMR.
AB-CHMINACA was added to the list of new psychoactive 
substances monitored by the EMCDDA and Europol through 
the European Union Early Warning System. A profile of the 
substance was created on the European Database on New 
Drugs (EDND). Since then, analytical details and other 
information, including a public health alert, have been 
exchanged between the EMCDDA, Europol, and the Member 
States, Turkey and Norway, on an ad hoc basis; the European 
Commission and the EMA have been kept duly informed.
 3.7  Information on whether or not the new 
psychoactive substance is already subject to 
control measures at national level in a Member 
State (Article 5.2(g) of the Council Decision)
Sixteen Member States (Belgium, Bulgaria, Croatia, Cyprus, 
Czech Republic, Estonia, Finland, France, Germany, Hungary, 
Italy, Latvia, Lithuania, Luxembourg, Slovenia and Sweden) 
and Turkey reported that AB-CHMINACA is controlled under 
drug control legislation. Information previously reported by 
Slovakia on the control status of AB-CHMINACA indicates that 
the substance is controlled under drug control legislation.
Two Member States (Austria and Poland) reported that 
AB-CHMINACA is controlled under specific new psychoactive 
substances control legislation.
Nine Member States (Denmark, Greece, Ireland, Malta, the 
Netherlands, Portugal, Romania, Spain and the United 
Kingdom) reported that AB-CHMINACA is not subject to 
control measures at the national level.
Norway reported that AB-CHMINACA is controlled under 
medicinal products legislation.
 3.8  Further information (Article 5.2(h) of the 
Council Decision)
3.8.1  The chemical precursors that are known to have 
been used for the manufacture of the substance
No information was reported by the Member States, Turkey, or 
Norway, about the chemical precursors or manufacturing 
methods used to make the AB-CHMINACA which has been 
detected within Europe.
The synthesis of (S)-AB-CHMINACA was first described in 
a 2009 patent (Buchler et al., 2009). More recently, the 
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synthesis of (S)-AB-CHMINACA has been described by 
Longworth et al. (Longworth et al., 2016).
The synthesis of (S)-AB-CHMINACA described by Longworth 
et al., started with 1H-indazole-3-carboxylic acid, which was 
subjected to Fischer esterification to give the corresponding 
methyl ester (methyl 1H-indazole-3-carboxylate). Alkylation of 
the ester with the appropriate bromoalkane ((bromomethyl)
cyclohexane), in the presence of potassium tert-butoxide 
produced methyl 1-(cyclohexylmethyl)-1H-indazole-3-
carboxylate. Saponification of the ester gave the acid 
1-(cyclohexylmethyl)-1H-indazole-3-carboxylic acid, which 
was then reacted with l-valinamide to produce (S)-AB-
CHMINACA (Longworth et al., 2016).
(R)-AB-CHMINACA could also be synthesised under identical 
conditions, using D-valinamide instead of l-valinamide. Using 
valinamide would produce racemic AB-CHMINACA 
(Moosmann et al., 2017).
According to Buchler et al. (Buchler at al., 2009) the starting 
compound methyl 1H-indazole-3-carboxylate, which is 
commercially available, can be prepared from 1H-indole-2,3-
dione (Johnson and Rodgers, 2005).
In summary, potential precursors of AB-CHMINACA are 
1H-indole-2,3-dione (20), 1H-indazole-3-carboxylic acid, 
methyl 1H-indazole-3-carboxylate, l-valinamide (for the 
synthesis of the (S)-enantiomer), valinamide for the racemic 
AB-CHMINACA and (bromomethyl)cyclohexane.
3.8.2  The mode and scope of the established or 
expected use of the new substance
No studies were identified that have examined the mode and 
scope of established or expected use of AB-CHMINACA. 
Given the limited information currently available, the relevant 
information has been included in the previous sections.
(20) A pre-precursor.
3.8.3  Other use of the new psychoactive substance 
and the extent of such use, the risks associated 
with this use of the new psychoactive 
substance, including the health and social risks
No information was provided by the Member States, Turkey or 
Norway that indicated that AB-CHMINACA had any other use 
apart from in analytical reference materials and scientific 
research.
From the available information, it does not appear that 
AB-CHMINACA is used in the manufacture of a medicinal 
product in the European Union. However, the data collection is 
incomplete and some countries indicated that this information 
is not known. It is understood that the collection of such 
information is a challenge in the absence of a database on the 
synthetic route of all medicinal products.
Eleven countries (Austria, Belgium, Croatia, Denmark, Finland, 
Greece, Italy, the Netherlands, Poland, Spain and the United 
Kingdom) reported that AB-CHMINACA is not used to 
manufacture a medicinal product for human use. Eight 
countries (Czech Republic, Estonia, Germany, Hungary, 
Ireland, Latvia, Norway and Sweden) reported that it was 
unknown if AB-CHMINACA is used to manufacture a medicinal 
product for human use.
In addition, the EMA reported that it is not known if AB-
CHMINACA is used in the manufacture of medicinal products 
for human use and which are centrally authorised within the 
European Union.
Eleven countries (Austria, Belgium, Denmark, Finland, France, 
Greece, Latvia, Poland, Slovakia, Spain and the United 
Kingdom) provided information that AB-CHMINACA is not 
used to manufacture a medicinal product for veterinary use. 
Seven countries (Estonia, Germany, Ireland, Norway, Portugal, 
Slovenia and Sweden) reported that it was unknown if 
AB-CHMINACA is used to manufacture a medicinal product 
for veterinary use.
In addition, the EMA reported that it is not known if AB-
CHMINACA is used in the manufacture of medicinal products 
for veterinary use and which are centrally authorised within 
the European Union.
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 4.  Information from the EMA (Article 5.3 
of the Council Decision)
Nineteen countries (Austria, Belgium, Croatia, Czech Republic, 
Denmark, Estonia, Finland, Germany, Greece, Hungary, 
Ireland, Italy, Latvia, the Netherlands, Norway, Poland, Spain, 
Sweden and the United Kingdom) reported that:
 ¡ AB-CHMINACA has not been granted a marketing 
authorisation as a medicinal product for human use;
 ¡ AB-CHMINACA is not the subject of an application for 
a marketing authorisation as a medicinal product for human 
use;
 ¡ there had been no cases of suspended marketing 
authorisation in respect to AB-CHMINACA as a human 
medicine.
Eighteen countries (Austria, Belgium, Denmark, Estonia, 
Finland, France, Germany, Greece, Ireland, Latvia, Norway, 
Poland, Portugal, Slovakia, Slovenia, Spain, Sweden and the 
United Kingdom) reported that:
 ¡ AB-CHMINACA has not been granted a marketing 
authorisation as a medicinal product for veterinary use;
 ¡ AB-CHMINACA is not the subject of an application for 
a marketing authorisation as a medicinal product for 
veterinary use;
 ¡ there had been no cases of suspended marketing 
authorisation in respect to AB-CHMINACA as a veterinary 
medicine.
The EMA also reported that AB-CHMINACA:
 ¡ has not been granted a marketing authorisation as 
a medicinal product for neither human nor veterinary use 
through the centralised procedure;
 ¡ is not the subject of an application for a marketing 
authorisation for neither human nor veterinary use through 
the centralised procedure;
is not the subject of a suspended marketing authorisation for 
neither human nor veterinary use through the centralised 
procedure.
I 5. Conclusion
AB-CHMINACA is a synthetic cannabinoid and a CB
1
 receptor 
agonist. It shares some pharmacological similarities with 
Δ9-tetrahydrocannabinol (THC), which is responsible for the 
major psychoactive effects of cannabis. In humans,  
AB-CHMINACA appears to cause effects that resemble 
those of cannabis and other synthetic cannabinoids.
AB-CHMINACA has been available in the European Union 
since at least February 2014. It has been detected in 
24 Member States, Turkey and Norway. More than 4 000 
seizures have been made within the European Union, which 
includes 43 kg of powder and 40 kg of herbal material which 
has been laced with AB-CHMINACA. This herbal material is 
typically sold as smoking mixtures; the products are marketed 
as ‘legal’ replacements to cannabis. Due to the way that these 
products are produced, it appears that users are at risk of 
serious poisoning. There are indications that the AB-
CHMINACA available on the market was synthesised by 
chemical companies based in China.
Thirty-one deaths with confirmed exposure to AB-CHMINACA 
have been reported by six Member States. In at least seven of 
the deaths, AB-CHMINACA was the cause of death or 
contributed to the death.
AB-CHMINACA is under assessment within the United Nations 
system. It will be assessed at the 39th meeting of the WHO 
Expert Committee on Drug Dependence (ECDD) that will be 
held in November 2017. Currently, neither a critical review nor 
a written recommendation had been published.  
AB-CHMINACA is not subject to control measures in 
nine Member States.
We conclude that the health and social risks caused by the 
manufacture, trafficking and use of AB-CHMINACA and the 
involvement of organised crime and possible consequences of 
control measures, could be thoroughly assessed through 
a risk assessment procedure in accordance with Article 6 of 
Council Decision 2005/387/JHA.
The EMCDDA and Europol will continue to intensively monitor 
AB-CHMINACA in order to ensure that new information is 
provided to the Member States, the EMA and the Commission 
via the information exchange of the European Union Early 
Warning System.
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I  Annex 1 Images from seizures and collected samples provided to the EMCDDA
Country Image Description
Slovakia Seizure, 12 May 2014
Green herbal particles, seized at  
Dunajská Streda
Seizing authority: Police
United Kingdom Collected sample, 19 May 2014
White powder
Collecting authority: WEDINOS
Finland Seizures, from 11 September 2014 to 16 
December 2014
Hashish-like material, seized at Helsinki
Seizing authority: Police
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Country Image Description
Italy Seizure, May 2015
Green herbal mixture, seized at Genova
Seizing authority: Police
Finland Seizure, 29 September 2016
Clear viscous liquid (“e-liquid”),  
seized at Turku
Seizing authority: Police
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I  Annex 2 Images from seizures provided to Europol
Country Image Description
Slovakia Seizure, 4 March 2014
White crystal, seized at Bratislava
Seizing authority: Police
Slovakia Seizure, 12 May 2014
Green herbal particles, seized at Dunajská 
Streda
Seizing authority: Police
Slovakia Seizure, 7 August 2014
Green herbal particles, seized at Saky
Seizing authority: Police
Slovakia Seizure, 22 September 2014
Green herbal particles, seized at Nitra
Seizing authority: Police
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Country Image Description
Italy Seizure, May 2015
Green herbal mixture, seized at Genova
Seizing authority: Police
Finland Seizure, 29 September 2016
Clear viscous liquid (“e-liquid”), seized at 
Turku
Seizing authority: Police
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